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Alternative splicing in Mo-MuLV recruits a splice donor site, SDV, within the gag that is required for optimal replication in vitro.
Remarkably, this SDV site was also found to be utilized for production of oncogenic gag-myb fusion RNA in 100% of murine-induced
myeloid leukemia (MML) in pristane-treated BALB/c mice. Therefore, we investigated the influence of silent mutations of SDVin this model.
Although there was no decrease in the overall incidence of disease, there was a decrease in the incidence of myeloid leukemia with a
concomitant increase in lymphoid leukemia. Importantly, there was a complete lack of myeloid tumors associated with 5V insertional
mutagenic activation of c-myb, suggesting the specific requirement of the SDVsite in this mechanism.
D 2004 Elsevier Inc. All rights reserved.
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Murine leukemia viruses (MuLV) belong to the simple
retrovirus family distinguishable by their elementary
genomic organization with the classical gag, pol, and env
genes. Although the simple retroviruses are defined as those
that have a one splicing event to produce a single-spliced
RNA that is used to encode Env, we showed the existence of
an alternatively spliced RNA (Dejardin et al., 2000). This
alternative event recruits a splice donor site (called SDV)
within the MuLV gag sequence which is conserved among
simple mammalian retroviruses, and leads to production of a
subgenomic 4.4-kb RNA. Point mutations of SDV that
maintained the wt Gag amino acid sequence affected viral0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.09.038
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E-mail address: mmougel@univ-montp1.fr (M. Mougel).RNA splicing and reduced viral replication in vitro (Dejardin
et al., 2000). In addition, the spliced SDVRNA acts as a
retroelement, since it is reverse transcribed and integrated
into the host genome of infected cells. It encodes a Gag–IN
fusion protein and like the genomic RNA, it is specifically
packaged in the progeny virions (Houzet et al., 2003). The
SDVsite may play a role in leukemogenesis, since the SDV
mutant virus, when inoculated into newborn Swiss mice,
leads to an extension of the Mo-MuLV leukemogenic
properties by an unresolved mechanism (Audit et al., 1999).
Replication competent MuLVs do not contain a trans-
duced cellular proto-oncogene within their genome and do
not transform cells in vitro. MuLVs, as many retroviruses,
induce tumors by insertion of viral DNA adjacent to or into
cellular oncogene regions, resulting in altered expression
and/or structure of the encoded proteins. This mechanism of
cellular oncogene activation, or less frequently, of tumor
suppressor gene inactivation, is known as insertional muta-04) 398–407
J.M. Ramirez et al. / Virology 330 (2004) 398–407 399genesis and contributes to clonal expansion of the infected
cell into a tumor (Rosenberg and Jolicoeur, 1997). MuLV
have been particularly useful for investigations of the
genetic basis of hematopoietic cancer because they can
induce the neoplastic disease in a reproducible way and also
provide an approach to identify genes important to trans-
formation. Retroviral DNA genomes integrate at essentially
random sites within the host genome as part of the viral
replication cycle (Withers-Ward et al., 1994). Nevertheless,
in multiple independent tumors, the same gene could be
targeted showing the existence of common integration sites
of murine retroviruses, providing genetic evidence that the
targeted gene plays a role in oncogenesis (Neel et al., 1981;
Nusse and Varmus, 1982). Large-scale use of retroviral
tagging has been recently conducted for the discovery of
genes involved in cancer (Kim et al., 2003; Li et al., 1999;
Lund et al., 2002; Mikkers et al., 2002; Suzuki et al., 2002).
In the case of the MuLV-induced myeloid leukemia
(MML) in pristane-treated mice, c-myb is the proto-
oncogene which is most frequently targeted by Mo-MuLV
(Nazarov and Wolff, 1995; Shen-Ong and Wolff, 1987). c-
myb regulates the transcription of several genes involved in
separate pathways of myeloid cell transformation: Bcl-2
(anti apoptosis), c-myc, c-kit (proliferation) and the tumor
suppressor gene encoding p15INK4b (growth arrest) (Hogg
et al., 1997; Wolff et al., 2001). In the MML model in adult
BALB/c mice, the multistep neoplastic process has been
dissected (Nason-Burchenal and Wolff, 1993). Activation of
c-myb by Mo-MuLV occurs early during the preleukemic
phase of the disease in hematopoietic tissues. Other steps
besides c-myb activation are required for development of
leukemia, since the activation occurs well before the
emergence of tumors. In this model, a chronic inflammation
induced by pristane in the peritoneal cavity is clearly
necessary for neoplastic progression of cells that have
activated c-myb (Nason-Burchenal and Wolff, 1992).
c-myb activation by MuLV in pristane-primed BALB/c
mice, results from proviral insertion into introns 2 or 3 or
more rarely into intron 1. Its expression at the RNA level is
constitutive due to the promoter activity of the long terminal
repeat. One of three novel gag–myb fusion RNAs is formed
using a splice donor site in MuLV gag and a splice acceptor
site at the next available downstream myb exon (Nason-
Burchenal and Wolff, 1993; Shen-Ong and Wolff, 1987).
This mechanism of activation was shown to be characteristic
of 100% of tumors induced by Mo-MuLV in this system.
This splice donor site for all of these transcripts precisely
corresponds to the SDVsite described in cells infected with
Mo-MuLV in vitro. Therefore, we wondered if inactivation
of the SDV splicing site might influence the incidence of
MML. Based on the evidence presented above, one might
predict that SDVinactivation would prevent formation of the
typical gag–myb fusion RNAs previously shown to be
involved in c-myb activation by Mo-MuLV. This could
result in a delay in induction or complete inhibition of the
MML, unless another splice donor site is recruited or a 3Vactivation mechanism is employed by the virus. Both of
these mechanisms are rational alternatives. For example, the
canonical splice donor (SD) is utilized by replication
competent avian leukemia viruses to activate c-myb (Jiang
et al., 1997). In addition, infrequent 3V integrations were
reported for F-MuLV induced myeloid leukemias in
pristane-treated mice and a Cas-Br-M virus induced myeloid
leukemia from a (NFS  DBA/2)F1 mouse (Nazarov and
Wolff, 1995; Shen-Ong et al., 1986).Results
Leukemogenicity of the SDVmutant MuLV in adult BALB/c
mice
The tumor-inducing potential of the SDVmutant virus
was determined by intravenous inoculation of young adult
pristane-primed BALB/c mice (Polony et al., 2003; Wolff
and Koller, 1990). For mice inoculated with wt virus, we
observed a mean latent period for leukemia development of
150 days with a 33% incidence of disease. These data
correlate with those commonly described for Mo-MuLV
(Shen-Ong and Wolff, 1987; Wolff et al., 1988). However,
there was a slightly lower overall disease incidence and
there was a higher incidence of lymphoid disease compared
to myeloid disease in the present experiment. Both of these
outcomes may have been due to the dilution of the wt virus
that was required for comparison to the mutant virus.
Examples of myeloid (WT4) and lymphoid (WT12) tumors
induced by wt virus are shown in Figs. 1b and d. Depicted
are cytospin preparations of cells from mouse spleens. The
lymphoid tumors were all characterized to be lymphoblastic
T cell lymphomas and all the myeloid tumors were
characterized as myeloid leukemias with maturation accord-
ing to a recent classification (Kogan et al., 2002). In Fig. 1b,
there is evidence of both immature myeloid cells and
maturing myelocytes.
We also found that 14 of the 36 mice inoculated with
the mutant virus developed leukemia (40% incidence) with
a latency period similar to that observed for wt MuLV,
demonstrating that the SDVmutation did not decrease the
viral pathogenicity and suggesting that it did not affect
spreading of the mutant virus in vivo. Of particular interest
was the finding that the SDV mutant virus induced a
different pattern of leukemias (Table 1). Specifically, there
was a profound decrease in the incidence of myeloid
tumors in the mutant virus group with 3% (only 1 case)
compared to 13% myeloid tumors in the wt group. These
data indicate that mutation of SDVreduces the Mo-MuLV’s
capacity to induce neoplastic myeloid disease. In contrast,
there was an increased incidence of lymphoid leukemia
(31%) in the mutant virus group compared to the wt group
(17%) (Table 1). Examples of the single myeloid tumor
(M6) and a representative lymphoid tumor (M2) induced
by the mutant virus are shown in Figs. 1a and c,
Fig. 1. Cytospin preparations of representative tumors in the spleen. M6 (a) and WT4 (b) were characterized as myeloid tumors with maturation. Mature
neutrophilic cells are evident as ring-forms and are indicated by arrows. M2 (c) and WT12 (d) were characterized as lymphoblastic T cell lymphomas. All
pictures were depicted with the same magnification and the scale bar in the lower right corner of panel d is 10 Am.
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mice had both myeloid marker-positive neoplastic cells
and lymphoid marker-positive neoplastic cells. One had
been inoculated with the wt virus (WT11) and two by the
mutant virus (M7 and M9). WT11 and M9 presented a
very similar picture. The spleen and liver metastasis
showed evidence of myeloid and lymphoid marker staining
within the same regions. An example of a segment of the
spleen is shown in Fig. 2 and is positive for CD3 (Fig.
2b), myeloperoxidase (Fig. 2c), and F4/80 (Fig. 2e). In the
case of M7, the white pulp was expanded with neoplastic
B cells that were positive for CD45R, while the red pulp
was expanded with neoplastic myeloid cells that were
positive for myeloperoxidase. It is possible that the two
tumor types within a given mouse had the same clonalTable 1
Induction of tumors by mutant and wt Mo-MuLVs
Virus Lymphoid tumors Myeloid tumors
Incidence (%)a Latency (average) Incidence (%)a
WT 5/30 (17) 89–199 (144) 4/30 (13)
Mutant 11/36 (31) 108–191 (150) 1b/36 (3)
a Incidence is the number of mice with neoplasms per total number of infected m
b This unique myeloid tumor did not have a provirus inserted at the 5Vend of the c
protein truncation.origin suggesting that the transformed cell is an early
progenitor or stem-like cell, but we do not have direct
evidence to support this.
It was important to determine whether the SDV
mutation was conserved in tumors produced by the
mutant virus. For this purpose, we amplified the gag
region where the silent mutations were introduced, using
tumor genomic DNA. The presence of the point mutations
was monitored by an analysis using HgaI digestion, since
the site-directed mutagenesis of the SDVsite creates a new
HgaI site, or by sequencing. Unambiguous sequencing of
a fragment of 343 nt (bp1450 to 1793), encompassing the
capsid region, revealed no detectable reversions or new
mutations in any of the mutant virus-induced tumors. The
HgaI digestions also showed the maintenance of theLymphoid/myeloid tumors
Latency (average) Incidence (%)a Latency (average)
74–138 (106) 1/30 (3) 194
122 2/36 (6) 122–132 (127)
ice. The latency period is given in days.
-myb locus, but had a provirus integrated in exon 9 resulting in mRNA and
Fig. 2. Analysis of splenic tissue from WT11. The mouse was diagnosed as having neoplastic disease(s) involving both myeloid and lymphoid cells. All panels
depict the same region with different stains: H and E (a) and immunohistochemical staining for CD3 (b), myeloperoxidase (c), CD45R (d) and F4/80 (e). The
scale bar in the lower right corner of panel d is 50 Am.
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shown). Therefore, no systematic reversions of the silent
mutations in SDV site occurred in the tumors induced by
mutant MuLV virus.
Clonality and high number of integration sites in tumors
induced by the SDVmutant
In order to examine the clonality and the presence of
MuLV proviral integrations in genomic DNA from tumors
induced in mice, genomic DNA was prepared from the
spleen tissues and digested with EcoRI, which does not cut
within the viral sequences. A Southern analysis was carried
out with a Mo-MuLV-specific U3 LTR probe (Figs. 3a and
4a). As shown in Fig. 3a, we observed that in the wt Mo-
MuLV-induced myeloid tumors, there were a small number
of integrations (1 or 2 per tumor) with sizes larger than the
size of the 8.2-kb provirus and this result was similar to that
which was published previously (Wolff and Koller, 1990;
Wolff et al., 1991). This was in contrast to the large number
of bands, up to 8 in WT8, observed for the lymphoid
tumors. This indicated that more insertion events by the
virus were required for development of the lymphomas
compared to myeloid neoplasms.
Analysis of DNA from tumors induced by the mutant
virus are presented in Fig. 4a. In this case, proviralintegrations appeared to be numerous in the majority of
neoplasms with more than 10 integrated proviruses in
tumors M4, M10, and M14. One exception was seen with
the unique myeloid neoplasm (M6), which harbored two
integration events. It was noted that for the lymphoid tumors
M4, M10, M14, and the unique myeloid M6, many of the
virus containing EcoRI fragments did not include complete
provirus, since the bands were shorter in size than those
expected following insertion of the complete 8.2 kb
provirus.
DNA analysis of proviral integrations
Since acute myeloid leukemias induced by Mo-MuLV
have previously been found to have c-myb gene rearrange-
ments in the 5Vend as a result of proviral insertion (Gonda
et al., 1987; Shen-Ong and Wolff, 1987; Shen-Ong et al.,
1986), the neoplasms were examined for alterations of c-
myb. Analyses were carried out by reprobing the Southern
blots shown in Figs. 3 and 4 with three different c-myb
probes (A, B, and C). Probe A was complementary to the
region located between c-myb exons 2 and 3, probe B to
the region overlapping exon 5, and probe C to exon 9 (Fig.
3c) (Mukhopadhyaya and Wolff, 1992). Lymphoid and
mixed lymphoid/myeloid neoplasms induced by either wt
or mutant virus did not show evidence of integrated virus in
Fig. 4. Southern analysis of proviral integrations in SDVmutant virus-
induced tumors. Genomic DNAs were visualized with 32P-labeled Mo-
MuLV U3 LTR (a) and c-myb C (b) probes. The positions of marker
fragments are indicated on the left. The genomic DNA fragment detected by
both the MuLV and myb C probes is indicated by a star. M, myeloid; L,
lymphoid.
Fig. 3. Southern analysis of integrated proviruses in wt Mo-MuLV tumors. DNAs were detected with either 32P-labeled Mo-MuLV U3 LTR probe (a) or c-myb
probe A or B (b). The locations of probes are indicated on the schematic map of c-myb and arrows indicate EcoRI sites (c). The positions of marker fragments
are indicated on the left. The genomic DNA fragments detected by both MuLV and myb probes are indicated by symbols (.Yn). Sizes are shown on the left.
M, myeloid; L, lymphoid, DBD, exons encoding DNA binding domain, TA, exons encoding the transactivation domain.
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induced with wt virus, however, were associated with
virus-related rearrangements at this locus (Fig. 3b). Tumors
had provirus insertion upstream of either exon 3 (WT4 and
WT7) or exon 4 (WT1 not shown, and WT5). The results
were confirmed with a Southern analysis conducted with
BamHI-digested tumor DNA (data not shown). These
insertion sites were similar in location to ones previously
seen in Mo-MuLV-induced MML (Shen-Ong and Wolff,
1987). Interestingly, none of these locations were found to
be sites of proviral insertion in DNA from the mutant virus-
induced tumors. Rather, the unique myeloid leukemia (M6)
induced by the mutant virus harbored a c-myb insertion
within exon 9 as detected by probe C (Fig. 4b). In contrast
to the provirus integrations observed in wt Mo-MuLV-
induced myeloid tumors, this latter integration (M6)
appeared as a short 2 kb-sized EcoRI fragment detected
by both the U3 LTR and myb probes (comparison between
Fig. 4a with b), which excludes the integration of the
complete 8.2 kb provirus. Such a short EcoRI fragment,
also observed in lymphoid M4, M5, M10, and M14
samples, could be generated by insertion of a deleted
MuLV or by the emergence of new EcoRI site(s)in the SDV
mutant provirus sequence as a result of spontaneous
mutations or recombination with endogenous viruses
(MCF, VL30, IAP,. . .).
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tumors
Analysis of c-myb transcripts was performed by North-
ern blot analysis of RNA extracted from splenic tissue.
Total RNA from normal and leukemic spleens was
visualized using a full-length cDNA myb probe (Fig. 5).
As shown in Fig. 5a, all of the wt-induced myeloid
leukemias expressed the normal-sized transcript of 3.9 kb
as well as a larger aberrant transcript, while the mixed
myeloid/lymphoid and lymphoid neoplasms expressed only
a normal transcript. The larger RNA species in the myeloid
neoplasms are presumed to be those initiated in the provirus
LTR (Shen-Ong and Wolff, 1987). Analysis of RNAs
extracted from tumors induced by the SDV mutant virus
revealed that all the neoplasms contained a normal-sized
myb transcript, with the exception of the tumor M6, which
expressed a shorter aberrant myb transcript (Fig. 5b).
Further RT-PCR analyses, using pairs of sense and
antisense primers from gag and myb, respectively, followed
by the sequencing of amplified DNA, were undertaken to
confirm the production of gag–myb fusion messages
(Nason-Burchenal and Wolff, 1993) (Fig. 6). Two different
products were detected, a 293-bp product for tumors with
provirus integrated upstream of exon 4 (WT1 and WT5)
and a 365-bp product for tumors with provirus integrated
upstream of exon 3 (WT7 and WT4) (Fig. 6a). It should be
noted that the truncated transcript observed in the M6
mutant tumor was not amplified in this RT-PCR assay (Fig.
4a), since it resulted from virus integration site in exon 9
(Fig. 4b). This type of integration, which would cause
truncation of the Myb C-terminus, has never been observed
before with wt Mo-MuLV-induced leukemias. IntegrationFig. 5. Northern blot analysis of myb RNA in wt (a) and mutant (b) Mo-MuLV tum
length c-myb cDNA probe. Normal-sized (3.9 kb) and abnormal or truncated c-myb
indicated on the left. M, myeloid; L, lymphoid.at the 3V end of c-myb was observed previously in Friend
MuLV strain FB29 leukemias and a Cas-Br-M-induced
leukemia (Mukhopadhyaya and Wolff, 1992; Shen-Ong et
al., 1986). Interestingly, C-terminal truncation by 240–248
aa has been demonstrated to increase the stability of the c-
myb protein by removing target sequences for 26S
proteasome degradation (Bies and Wolff, 1997). In addition,
it causes an increase in transactivation activity by removing
the negative regulatory domain (Ferrao et al., 1995;
Kalkbrenner et al., 1990; Kanei-Ishii et al., 1992; Sakura
et al., 1989).
Differences between myeloid incidences of wt and
mutant viruses were evaluated by using the m2 t test and
considered significant when probability value (P) was
b0.05. Finally, these results reveal that the SDVmutation
prevents development of myeloid tumors involving 5V
integration and promoter insertional mutagenesis (incidence
0/36, P b 0.03). Since integration at the 5V end and
activation by promoter insertion appear, from past studies,
to be the most efficient mechanism of activation of c-myb,
blocking of this mechanism by mutation of the splice site
would be presumed to result in an overall reduction in
myeloid tumors. Indeed, we observed a significant decrease
in incidence of myeloid tumors.
Generation of MCF viruses
Mo-MuLV is known to frequently generate, in most
strains of mice, recombinant viruses called mink cell focus-
forming viruses (MCFs). These are recombinants between
the infecting ecotropic Mo-MuLV and endogenous poly-
tropic virus sequences which encode the receptor-binding
domain of env. The new receptor binding domain providesors. Total RNA isolated from leukemic tumors was hybridized with a full-
transcripts are indicated on the right. The positions of marker fragments are
Fig. 6. RT-PCR amplified products showing the expression of gag-myb RNA in leukemic tumors. (a) Total RNA from normal (control) or leukemic spleens
was reverse transcribed and subjected to amplification with gag and myb primers. RNA from tumor 2B-4-7 was used as a positive control (Nason-Burchenal
and Wolff, 1993). (b) Map of amplified products as revealed by sequencing; arrows represent primers in the gag and myb positions used for amplification.
Position of the splicing junction is indicated (SDV/SA). M, myeloid; L, lymphoid.
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mitogenic. Because the generation MCFs has been asso-
ciated primarily with the efficient induction by Mo-MuLVof
T-lymphomagenesis (Fan, 1997), we determined whether
theses viruses were associated with disease induced by wt
and mutant viruses in this study. Neoplasms were examined
for the presence of MCF envelope protein by Western blot
analyses with monoclonal antibody 7C10. As shown in Fig.
7, a large majority of both lymphoid and mixed lymphoid/
myeloid neoplasms were associated with the expression of
MCF envelope protein. In contrast, the formation of MCF
recombinants was not associated with the induction of
myeloid disease, including the mutant-induced myeloid
neoplasm (M6) with the provirus exon 9 insertion (Fig.
5). These results correlated with those described for a Mo-
MuLV recombinant (MoL4070LTR) that induced myeloid
disease in newborn BALB/c mice (Wolff et al., 2003).Discussion
In conclusion, our data suggest that the Mo-MuLV
alternative donor splice site, SDV, is required for myeloid
tumor development involving activation of c-myb by aFig. 7. Detection of MCF viral envelope protein in neoplasms. Total protein extr
(7C10) which specifically recognizes MCF envelope (Wolff et al., 2003). To cont
goat polyclonal anti-actin antibody. M, myeloid; L, lymphoid.promoter insertion/splicing mechanism, since there was no
activation of c-myb by this mechanism with the replication-
competent SDVmutant virus. The particular requirement of
SDV was reinforced by the fact that in the absence of a
functional SDV splice site, no other putative splicing sites
were utilized (Fig. 5b). For instance, one might expect
recruitment of the upstream canonical env splice donor site,
as observed in rapid-onset B-cell lymphomas induced by the
avian leukosis virus in chicken embryos (Jiang et al., 1997;
Smith et al., 1997). Interestingly, in the latter model, the
negative regulator of splicing (NRS) (which includes an
inactive splice donor site) within the matrix protein domain
was also found to participate in the development of c-myb-
associated neoplasms. But in contrast to our system,
disruption of the NRS promotes c-myb activation through
splicing (Polony et al., 2003), while inactivation of the SDV
site in Mo-MuLV prevents c-myb activation with an
associated increase in neoplasms not associated with inser-
tional mutagenesis of c-myb. The comparison of both avian
and murine systems suggests that NRS and SDVact precisely
in an opposite manner.
A great deal has been learned regarding the specific
sequence determinants of disease specificity within the U3
region of the LTR for Mo-MuLV and Friend (Fr) MuLV-acted from splenic tissues was analyzed by Western blot with an antibody
rol for protein loading in samples, the blot were stripped and analyzed with
J.M. Ramirez et al. / Virology 330 (2004) 398–407 405induction of lymphoid and erythroid leukemia, respectively
(reviewed in references (Tsichlis and Lazo, 1991) and
(Athas et al., 1994)). However, only two studies have
addressed the specific sequences required for disease
specificity in the case of c-myb associated-myeloid neo-
plasms which occur in MuLV-infected and pristane-treated
mice. Instead of the LTR, two other regions, Psi-gag-PR and
env, were shown to be responsible for the different abilities
of F-MuLV and Mo-MuLV to induce myeloid leukemia in
pristane-treated mice (Mukhopadhyaya et al., 1994; Wolff
and Koller, 1990). The SDV site is within the Psi-gag-PR
region and thus probably is an important element, but the
difference in the ability of the two viruses to activate c-myb
cannot be explain simply by the presence or absence of SDV
in Mo- and Fr-MuLV, respectively, since the alternative
splicing via the SDV site occurs in the life cycle of both
viruses. However, splicing regulation in the two viruses is
likely to differ because inhibition of alternative splicing has
been shown to cause a 10-fold stronger reduction in viral
replication of F-MuLV compared with Mo-MuLV (Dejardin
et al., 2000).
In mice, Mo-MuLV-induced T-lymphomas show pre-
dominantly activations of the proto-oncogenes c-myc, pim-
1, and pvt-1. It would be interesting to know if the group of
T- cell lymphomas in the present study, particularly those
induced by the mutant virus, resulted from activation of a
similar or different set proto-oncogenes. It remains to be
determined if the SDV mutation might influence the
integration target gene selection.
It was found here that both lymphoid and mixed
lymphoid/myeloid neoplasms, in contrast to myeloid leuke-
mias, express MCF virus envelope protein and we have,
therefore, considered the possibility that there is a con-
nection between the virus’s ability to generate MCFs and the
capacity to induce lymphoid neoplasms. This might explain
why the mutant virus had a propensity to induce lymphoid
disease. Recombinational events such as those that generate
MCFs may occur during reverse transcription of two
copackaged RNAs into DNA during infection of a new
host cell or by recombination within the chromosomal DNA
of the cell (see review (Muriaux and Rein, 2003)). During
the virus life cycle, the 4.4 kb subgenomic SDVRNA shares
the same properties as the viral genomic RNA, including
specific packaging, reverse transcription, and integration.
Thus, one could hypothesize that in the absence of the SDV
RNA escort, the genomic RNA could be copackaged more
often with defective endogenous retroviruses (e.g., MCF)
favoring recombination events. This could explain the new
leukemogenic properties of the SDVmutant virus.
A simple alternative explanation for an increased
incidence of lymphoid disease induction by the mutant
virus is that in the absence of efficient induction of myeloid
disease by promoter insertion and activation of the c-myb
gene, lymphoid disease, which has a somewhat longer
average latency, has a chance to fully develop. Death due to
myeloid disease may prevent the progression of lymphoidtumors from existing preleukemic cells. In previous studies,
effects of the SDVmutation were monitored on cells infected
in vitro and we showed that the SDVmutant virus loses its
ability to produce the 4,4 kb subgenomic RNA (RNA SDV)
as well as the encoded Gag–Pol fusion protein. While we
showed by trans-complementary experiments that the SDV
RNA production is required for the optimal virus replica-
tion, the role of the SDV-encoded protein remains unknown
(Houzet et al., 2003). Therefore, it will be interesting to
investigate whether the participation of the SDVsplicing site
in tumorigenesis might also lie in the spliced SDVRNA and/
or the SDV-encoded Gag/IN protein.Materials and methods
Virus inoculation and analysis of tumors
The tumor-inducing potential of the SDVmutant virus
was determined by intravenous inoculation of young adult
pristane-primed BALB/c mice as described in Polony et al.
(2003) and Wolff and Koller (1990). For the production of
virus for inoculation of mice, NIH3T3 cells were infected
with viral stocks produced by Dunni cells transfected with
mutant and wild-type ecotropic Mo-MuLV (strain 8.2) and
titrated by RT assay and FIA with monoclonal antibody
H538 as described in Dejardin et al. (2000). The SDV
Moloney mutant (M1), with three nucleotide substitutions
in positions 1598, 1599, and 1601 in the SDVsplice donor
site, showed a 10-fold titer reduction relative to the wt Mo-
MuLV (Dejardin et al., 2000) and in order to normalize the
virus load inoculated in mice, wt virus was diluted
accordingly. BALB/cAnNCr mice were injected intraper-
itoneally with 0.5 ml of pristane at 4–6 weeks of age and
after 18 days were intravenously inoculated with 0.5 ml of
virus corresponding to 7  105 RT cpm. Mice were housed
and cared for in accordance with the recommendations of
the Guide for the Care and Use of Laboratory Animals and
monitored routinely for evidence of disease. Cytospins
were prepared from enlarged spleens, and the cells were
stained in Diff-Quik (Dade Behring AG). Spleen, liver,
thymus, tumor cell-infiltrated granuloma, and affected
lymph nodes were fixed in Fekete’s modification of
Tellyesniczky’s fluid (Fekete, 1938), processed in paraffin,
and stained with hematoxylin and eosin (H&E). Immuno-
histochemistry was also performed with the following
antibodies: rabbit anti-CD3 (Dako), rat anti-mouse F4/80
(Serotec), rabbit anti-human myeloperoxidase (Dako) and
biotinylated rat anti-mouse CD45R (B220). Detection of
primary antibodies was carried out with secondary anti-
bodies where applicable and ABC reagent (Vector Labo-
ratories). Tumors were phenotyped based upon the
morphology of transformed cells in the spleen, liver, and
granuloma and upon results of immunohistochemistry. T
cells are positive for CD3, B cells for CD45R, and myeloid
cells for myeloperoxidase or F4/80.
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Splenic tissues (0.2 g) were treated with proteinase K
(100 Ag/ml) in 0,1M NaCl-0,05M Tris–HCl (pH 8)-0,05M
EDTA-0,5% SDS containing 20 mg/ml of RNaseA.
Following an overnight incubation at 50 8C, samples were
extracted two times with phenol and one time with phenol/
chloroform and ethanol precipitated. Samples (15 Ag) were
digested with EcoRI or BamHI overnight at 37 8C,
electrophoresed on a 0,7% agarose gel, blotted onto a
Nytran membrane (Schleicher and Schuell ) and hybridized
with either a 32P-labeled Mo-MuLV U3 LTR probe or c-myb
probe A or B or C as described in detail (Nazarov and
Wolff, 1995; Wolff et al., 1988, 1991).
RNA analysis
Total RNA was isolated from 25 mg normal and
leukemic spleens as described in Mukhopadhyaya et al.,
1992, with RNeasy (Qiagen) according to the manufactur-
er’s instructions. For Northern blot analysis, RNA samples
(5 Ag) were electrophoresed on a 1.2% agarose form-
aldehyde gel, blotted onto a Nytran membrane (Schleicher
and Schuell), and hybridized with a full-length c-myb cDNA
probe as described (Nazarov and Wolff, 1995). The probe
was 32P-labeled with Read-To-Go DNA labeling beads
(Amersham Pharmacia Biotech).
RT-PCR amplification was performed with the Titan
One tube RT-PCR system (Roche) with gag (5VGGACTC-
TGCTGACCGG3V) and myb (5VCAGACCAACG-
CTTCGGACC3V) primers and loaded on an ethidium
bromide-stained 2% agarose gel.
Western immunoblotting
Frozen splenic tissues were powdered and disrupted in
cold lysis buffer (20 mM Tris–HCl (pH 7.5), 50 mM NaCl,
0.5% Nonidet P-40, 0.5% SDS, and 0.5% sodium deoxy-
cholate) supplemented with a mixture of protease inhibitors
(Completek, Roche Molecular Biochemicals). Tissue
lysates were sonicated for 30 s and clarified by centrifuga-
tion at 13,000 rpm for 15 min at 4 8C. Precleared lysates (25
Ag) were fractionated by SDS-PAGE on an 8% gel, and
electrophoretically transferred to a nitrocellulose membrane
(Invitrogen). Immunoblots were incubated either with
monoclonal antibody 7C10 (Wolff et al., 1982) or poly-
clonal goat anti-actin antibody (sc 1616, Santa Cruz
Biotech.) and visualized with SuperSignal West Pico
chemiluminescent substrate (Pierce) in accordance with
the manufacturer’s instructions.Acknowledgments
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